Key result
Systemic inflammatory markers link to peri-coronary fat attenuation index.
Why the study?
Inflammation is linked to increased cardiovascular disease risk in people with HIV on antiretroviral therapy, but whether the fat attenuation index correlates with soluble inflammatory markers is unknown.
Are soluble inflammatory markers associated with peri-coronary artery inflammation (measured by FAI) in people with and without HIV?
Cross-Sectional (n=74)
Are soluble inflammatory markers associated with peri-coronary artery inflammation (measured by FAI) in people with and without HIV?
Systemic inflammatory markers are associated with peri-coronary inflammation (FAI) on CCTA, suggesting their potential combined use as noninvasive biomarkers for asymptomatic CVD risk assessment.
Background: Inflammation is linked to elevated cardiovascular disease (CVD) risk in people with HIV (PWH) on antiretroviral therapy (ART). Fat attenuation index (FAI) is a measure of peri-coronary inflammation that independently predicts CVD risk in HIV-uninfected persons. Whether FAI is associated with soluble inflammatory markers is unknown. Methods: Plasma levels of inflammatory markers were measured in 58 PWH and 16 controls without current symptoms or prior known CVD who underwent coronary computed tomography angiography and had FAI measurements. A cross-sectional analysis was performed, and associations of markers with FAI values of the right coronary artery (RCA) and left anterior descending artery (LAD) were assessed using multivariable regression models adjusted for the potential confounders age, sex, race, low-density lipoprotein cholesterol, body mass index, and use of lipid-lowering medication. Results: Several inflammatory markers had significant associations with RCA or LAD FAI in adjusted models, including sCD14, sCD163, TNFR-I, and TNFR-II, CCL5, CX3CL1, IP-10. Conclusions: The associations between indices of systemic and peri-coronary inflammation are novel and suggest that these systemic markers and FAI together are promising noninvasive biomarkers that can be applied to assess asymptomatic CVD in people with and without HIV; they also may be useful tools to evaluate effects of anti-inflammatory interventions.
No takes yet. Share an insight, caveat, or question.
Freeman et al. (2023) conducted a cross-sectional in HIV infection without cardiovascular disease (n=74). Soluble markers of inflammation was evaluated on Association of inflammatory markers with fat attenuation index (FAI) values of the right coronary artery and left anterior descending artery. Systemic inflammatory markers, including sCD14, sCD163, and TNFR-I/II, were significantly associated with peri-coronary fat attenuation index in adjusted multivariable regression models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: